Efficacy of desmopressin in patients with multiple sclerosis suffering from bladder dysfunction: a meta-analysis.

R Bosma, K Wynia, E Havlíková, J De Keyser, Berrie Middel

Journal: Acta neurologica Scandinavica 2005;112(1):1-5

PMID: 15932348

Abstract

OBJECTIVES

The current review evaluates the safety and efficacy of desmopressin in patients with multiple sclerosis (MS) who suffer from both daytime and nocturnal voiding frequency and from incontinence.

MATERIALS AND METHODS

A literature search was carried out looking for studies published between 1990 and 2003 which evaluated desmopressin in MS patients with bladder dysfunction.

RESULTS

The grand total mean effect sizes show the following estimates of clinical relevant differences: desmopressin has a moderate effect on the number of voids during the day or during the night over a period of 6 h after taking the drug. A large effect associated with the use of desmopressin was detected by the mean difference in urine volume (ml) in 6 h. A small effect was detected in the mean 24-h urine volume. Serum sodium levels were combined with plasma osmolality in some studies and were found to be not significantly affected by desmopressin treatment.

Copyright Blackwell Munksgaard 2005.

Address: Department of Health Sciences, Faculty of Medical Sciences, University Medical Center Groningen, Groningen, The Netherlands.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.